BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s00280-021-04234-0.pdf
Reference20 articles.
1. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339
2. Robert C, Grob JJ, Stroyakoskiy D, Karaszewska B, Hauschild A, Levchenko E et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381:626–636. https://doi.org/10.1056/NNJMoa1904059
3. Larkin JMG, Yan Y, McArthur GA, Ascierto PA, Liszkay G, Mandala MM et al (2015) Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 33S:9006–9006. https://doi.org/10.1200/jco.2015.33.15_suppl.9006
4. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603–615. https://doi.org/10.1016/S1470-2045(18)30142-6
5. Planchard D, Besse B, Kim TM, Quoix EA, Souquet PJ, Mazieres J et al (2017) Updated survival of patients with previously treated BRAF V600E-mutant advanced non-small cell lung cancer who received dabrafenib or D + trametinib in the phase II BRF113928 study. J Clin Oncol 35(15):9075–9075. https://doi.org/10.1200/JCO.2017.35.15_suppl.9075
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer;Targeted Oncology;2024-08-10
2. Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience;Mutagenesis;2024-05-22
3. Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives;International Journal of Molecular Sciences;2024-01-05
4. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial;Nature Medicine;2023-04-14
5. The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal?;Cancers;2022-08-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3